Troglitazone

Drug Profile

Troglitazone

Alternative Names: CI 991; CS 045; GR 92132; GR 92132X; Noscal; Prelay; Rezulin; Romozin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Pfizer
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Apoptosis stimulants; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Market Withdrawal Type 2 diabetes mellitus
  • Discontinued Cancer; Female infertility; Polycystic ovary syndrome

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-III for Polycystic ovary syndrome in USA (unspecified route)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 27 May 2003 A preclinical study has been added to the Women's Health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top